| BIOGEN INC | 259.75 / -0.36% |
| Date/Time | 11/21 / 17:32 |
| Chg. / Chg.(%) | -0.95 / -0.36% |
| Bid | - |
| Ask | - |
| Open | 257.45 |
| Previous Close | 260.70 |
| High | 259.75 |
| Low | 257.45 |
| Volume [EUR] | 24,310.75 |
| Volume [Units] | 94 |
| Price fixings | 4 |
| ISIN | US09062X1037 |
| Security | BIIB |
| Exchange | Vienna Global Market |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| TradeGate | 260.850 |  |
4 |
| München | 258.65 | |
0 |
| Hamburg | 258.75 | |
0 |
| Düsseldorf | 258.60 |  |
0 |
| Berlin | 260.05 | |
0 |
| Hannover | 258.75 | |
0 |
| Lang & Schwa.. | 259.300 | |
|
| gettex | 260.900 | |
|
| Stuttgart | 258.550 | |
|
| NASDAQ | 288.4600 | |
1,292,420 |
| Cboe US | 288.62 | |
92,192 |
| IEX | 288.51 | |
39,017 |
| London Inter.. | 287.50 | 815 | |
| Frankfurt | 257.1500 | 210 | |
| Xetra | 260.20 | |
126 |
| Vienna Globa.. | 259.75 | |
94 |
| SIX Swiss Ex.. | 232.00 | |
|
| Mexico | 5,600.00 | 113 |
News
- Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
11/21/2019 / 13:30 - GlobeNewswire - Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer
11/18/2019 / 22:05 - GlobeNewswire - UPMC Health Plan and Biogen Announce Groundbreaking Value-Based Agreement for Multiple Sclerosis Treatments
11/14/2019 / 16:43 - GlobeNewswire - US stocks close mixed, Dow hits all-time high
11/13/2019 / 22:00 - TeleTrader - Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary
11/12/2019 / 14:00 - GlobeNewswire
Real-time